Genomic profiling of sporadic multiple meningiomas

E Zeynep Erson-Omay1,2,3, Shaurey Vetsa4,5,6, Sagar Vasandani4,5,6

  • 1Department of Neurosurgery, Yale School of Medicine, 15 York St, LLCI 810, New Haven, CT, 06520-8082, USA. zeynep.erson@yale.edu.

Abstract

Insights

Multiple meningiomas (MMs) can arise from a single clone, even without NF2 mutations, and develop distinct molecular profiles. This suggests individualized treatment strategies are essential for managing MMs in patients.

Area of Science:

  • Neuro-oncology
  • Genomics
  • Tumor Biology

Background:

  • Multiple meningiomas (MMs) rarely occur sporadically, and the molecular mechanisms of their formation and clonal etiology are poorly understood.
  • It remains unclear if individual tumors within a single patient exhibit similar behavior.

Purpose of the Study:

  • To investigate the clonal origin and molecular characteristics of sporadic multiple meningiomas.
  • To determine if tumors within a single patient share a common clonal origin or arise independently.

Main Methods:

  • Comprehensive next-generation sequencing of 15 meningiomas and 1 dural specimen from 6 patients with sporadic MMs.
  • Analysis of clinical data, including tumor grade and spatial separation.

Main Results:

  • 11/15 tumors were NF2-loss subtype; 5/6 patients had MMs of monoclonal origin.
  • One patient showed independent clonal formation, and a novel non-NF2 mutant MM with monoclonal etiology was identified.
  • Monoclonal MMs exhibited inter-tumoral heterogeneity due to branched evolution, and Grade I and II meningiomas occurred in the same patient.

Conclusions:

  • Both NF2-loss and non-NF2 driven MMs can originate from monoclonal expansion and develop heterogeneity.
  • The molecular profile and clinical behavior of one meningioma cannot predict another within the same patient.
  • Individualized clinical management strategies are recommended for patients with multiple meningiomas.

Related Concept Videos